- Volume 14 Issue 1
DOI QR Code
Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study
- Uysal-Sonmez, Ozlem (Department of Medical Oncology, Sakarya University Education and Research Hospital) ;
- Tanriverdi, Ozgur (Department of Medical Oncology, Mugla Sitki Kocman University Education and Research Hospital) ;
- Esbah, Onur (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
- Uyeturk, Ummugul (Division of Medical Oncology, Department of Internal Medicine, Abant Izzet Baysal University Faculty of Medicine) ;
- Helvaci, Kaan (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
- Bal, Oznur (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
- Yalcintas-Arslan, Ulku (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
- Budakoglu, Burcin (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
- Oksuzoglu, Berna (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital)
- Published : 2013.01.31
Background: Malignant melanoma is a cancer that demonstrates rapid progression and atypical clinically features with a poor prognosis. Aim: This study was performed to determine the clinical characteristics and treatment outcomes of patients with malignant melanoma in Turkey. Methods: The medical records of 98 patients between 2007-2012 at our centers were retrieved from the patient registry. Overall survival (OS) was calculated using the Kaplan-Meier method. Results: In our study, with the median follow-up of all patients with cutaneous MM of 46.3 months, the median OS rate of all cases was 43.6 months and 5-year OS was 48.6%. However, five-year OS rates of patients with localized disease (stage I-II) and node involvement (stage III) were 60.3% and 39.6%, respectively. The median OS of stage IV patients was 8.7 months and 1-year OS rate was 26.2%. We showed that advanced stage, male gender, and advanced age in all patients with MM were significant prognostic factors of OS. Conclusions: Compared with the results of current studies from Western countries, we found similar findings concerning demographical features, histological variables and survival analyses for our patients with cutaneous MM in Turkey.
- Hainsworth JD, Infante JR, Spigel DR, et al (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah cannon oncology research consortium. Cancer, 116, 4122-9. https://doi.org/10.1002/cncr.25320
- Hauschild A, Agarwala SS, Trefzer U, et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 27, 2823-30. https://doi.org/10.1200/JCO.2007.15.7636
- Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
- Lasithiotakis K, Leiter U, Meier F, et al (2008). Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 112, 1795-804. https://doi.org/10.1002/cncr.23359
- Lindholm C, Andersson R, Dufmats M, et al (2004). Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer, 101, 2067-78. https://doi.org/10.1002/cncr.20602
- MacKie RM, Bray C, Vestey J, et al (2007). Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer, 96, 1772-7. https://doi.org/10.1038/sj.bjc.6603801
- Markovic SN, Erickson LA, Rao RD, et al (2007). Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc, 82, 490-513. https://doi.org/10.4065/82.4.490
- Mervic L (2012). Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerologica, 21, 27-31.
- O'Day S, Hodi FS, McDermott DF, et al (2010). A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol, 28, 4. https://doi.org/10.1200/JCO.2009.23.3890
- Reed KB, Brewer JD, Lohse CM, et al (2012). Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc, 87, 328-34. https://doi.org/10.1016/j.mayocp.2012.01.010
- Spatz A, Cook MG, Elder DE, et al (2003). Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer, 39, 1861-5. https://doi.org/10.1016/S0959-8049(03)00325-3
- Tas F, Kurul S, Camlica H, Topuz E (2006). Malignant melanoma in Turkey: a single institution’s experience on 475 cases. Jpn J Clin Oncol, 36, 784-9.
- Thompson JF, Soong SJ, Balch CM, et al (2011). Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol, 29, 2199-205. https://doi.org/10.1200/JCO.2010.31.5812
- Uehara S, Kamo R, Harada T, Ishii M (2009). Survival analysis of malignant melanoma in Japan-multivariate analysis of prognostic factors. Osaka City Med J, 55, 35-52.
- Verma S, Quirt I, McCready D, et al (2006). Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer, 106, 1431-42. https://doi.org/10.1002/cncr.21760
- Balch CM, Buzaid AC, Soong SJ, et al (2001). Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol, 19, 3635-48.
- Barnhill RL, Fine JA, Roush GC, Berwick M (1996). Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 78, 427-32. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<427::AID-CNCR8>3.0.CO;2-G
- Chao C, Martin RC, Ross MI, et al (2004). Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol, 11, 259-64. https://doi.org/10.1245/ASO.2004.04.015
- Chi Z, Li S, Sheng X, et al (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer, 11, 85-95. https://doi.org/10.1186/1471-2407-11-85
- Gimotty PA, Botbyl J, Soong SH, Guerry D (2005). A population-based validation of the American Joint Committee on Cancer melanoma staging systemç. J Clin Oncol, 23, 8065-75. https://doi.org/10.1200/JCO.2005.02.4976
- Assessing a Sun Protection Program Aimed at Greek Elementary School Students for Malign Melanoma Prevention vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.5009
- A Retrospective Multicenter Evaluation of Cutaneous Melanomas in Turkey vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10451
- Tumors Involving Skin, Soft Tissue and Skeletal Muscle: Benign, Primary Malignant or Metastatic? vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6681
- The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0440-7
- An update on cutaneous melanoma in Turkey: evaluation of 19-year data in a single tertiary centre and review of the literature vol.31, pp.2, 2016, https://doi.org/10.1111/jdv.13866